Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kronos’ Bischofberger Turns To Gilead SYK Inhibitors To Jump Start R&D

Executive Summary

Two years after Bischofberger left Gilead for Kronos, he called upon former colleagues to acquire a SYK inhibitor program for a genetically defined subset of acute myelogenous leukemia.

You may also be interested in...



Deal Watch: Roche Partners With Jnana On Cellular Metabolism Approach To Disease

Pharma and the US biotech will target key regulators of cellular metabolism with focus on immune and neurological disorders. Royalty Pharma buys portion of PTC’s royalty rights to risdiplam, under development at Roche.

Finance Watch: High Value Of Exits Keep Biopharma VC Deals At Near-Record Levels

Private Company Edition: IPOs and M&A are returning money to investors, who are putting that money into new investments. Also, the mega-push in VC mega-rounds continues, including $105m for Kronos, and RA Capital raises it first VC fund.

Former Gilead CSO Bischofberger Lands At Kronos As C-Suite Moves To Start-Ups Continue

Norbert Bischofberger returns to his start-up roots, exiting Gilead after nearly 30 years to become CEO of Kronos, which is developing novel drugs directed at tough cancer targets. He's one of several big pharma/large biotech executives to venture recently into entrepreneurial opportunities.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel